Zunera Khan

TL;DR: Pimavanserin showed efficacy in patients with Alzheimer's disease psychosis at the primary endpoint (week 6) with an acceptable tolerability profile and without negative effect on cognition.

TL;DR: Novel findings show that MBI is associated with faster decline in attention and working memory in this cognitively normal sample, raising the possibility that M BI represents a novel target for dementia clinical trials or prevention strategies.

TL;DR: It is shown that experiencing loneliness and decreased physical activity are risk factors for worsening mental health during the pandemic and the need to examine policies which target these potentially modifiable risk factors is highlighted.

TL;DR: While reductions in antipsychotic use can be achieved by using a "real world" intervention, this may not be of benefit to people with dementia in the current climate of more judicious prescribing unless nonpharmacological interventions such as social interaction or exercise are provided in parallel.

TL;DR: There is evidence from a modest number of well-conducted randomized controlled trials (RCTs) that various nonpharmacological approaches, including cognitive training, cognitive rehabilitation, and cognitive stimulation therapy (CST), confer modest but significant benefits in the treatment of cognitive symptoms in people with AD.